(Q45404021)

English

Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

3

object named as

Yasemin Suezer

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Adriaan F G Antonis

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Robbert G van der Most

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Norbert Stockhofe-Zurwieden

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Franz Daus

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Remco S Schrijver

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

20 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

4818-4827

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Respiratory syncytial virus: reverse genetics and vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

MVA: a cuckoo in the vaccine nest?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Transient host range selection for genetic engineering of modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Improved host range selection for recombinant modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Experimental reproduction of respiratory disease in calves with non-cell-culture-passaged bovine respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Type-specific serologic diagnosis of respiratory syncytial virus infection, based on a synthetic peptide of the attachment protein G.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

The acute phase response of haptoglobin and serum amyloid A (SAA) in cattle undergoing experimental infection with bovine respiratory syncytial virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Monoclonal antibodies against bovine immunoglobulins and their use in isotype-specific ELISAs for rotavirus antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Immunopathogenesis of vaccine-enhanced RSV disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

RSV-induced immunopathology: dynamic interplay between the virus and host immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant poxviruses as mucosal vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.04.002

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45404021&oldid=2076639513"